Mani Subramanian, MD, PhD

Dr. Subramanian is a clinician-scientist with extensive experience in drug development for over 20 years. Most recently he was senior vice president and therapeutic area head of liver diseases at Gilead Sciences. There he oversaw the development of a portfolio of novel therapeutics and translational research programs for the treatments of viral hepatitis, nonalcoholic steatohepatitis, cholestatic liver disease, alcoholic hepatitis, and inflammatory bowel disease. These led to 6 NDAs in viral hepatitis Sovaldi® (2013), Harvoni® (2015), Epclusa® (2016) and Vosevi® (2017), sNDAs for pediatric and other patient populations with Hepatitis C, and Vemlidy® (2017), sNDAs for Viread^® for the prevention of mother-to-child transmission and for the treatment of pediatric patients with Hepatitis B.

Previously, Mani was at Human Genome Sciences where he worked on several monoclonal antibodies and albumin fusion proteins, and oversaw the clinical development of Albuferon®, a novel albumin-fused interferon for the treatment of viral hepatitis. He was a key member of the team at Celera Genomics that sequenced the human, mouse and anopheles genomes. Dr. Subramanian has authored over 160 publications including in NEJM, Lancet, JAMA, Science, Nature, Hepatology, and Gastroenterology.